Meet WR Hambrecht + Co at the Annual Healthcare Conference
It has been 34 years since Hambrecht & Quist (H&Q) held the first Healthcare Conference in San Francisco at the Westin St. Francis Hotel in January, 1983. Presenting companies at the first H&Q Conference included hospital operators, medical device manufacturers, a medical information services provider, and five biotechnology startup firms: Centocor, Collagen, Genentech, Monoclonal Antibodies, Inc. and Xoma.
The Conference has been an extraordinarily popular annual event since then. In 1999, after acquisitions, this must-attend meeting was renamed the Chase H&Q Healthcare Conference, then the J.P. Morgan Healthcare Conference. WR Hambrecht + Co, like its predecessor firm Hambrecht & Quist, seeks to identify high prospects growth-stage companies, and provide them with access to the much-needed capital necessary to fund development, marketing and infrastructure allowing them to achieve their full potential.
“We at WR Hambrecht + Co continue to be astonished at the energy, inventiveness and sheer horsepower exhibited by early stage life sciences companies out to improve the human condition and build significant enterprises along the way,”
WRH+Co’s Regulation A+ strategy is a continuation of Bill Hambrecht’s legacy of conducting small public offerings for what were once considered high-risk start-ups and are now household names and Fortune 500 companies. Currently WR Hambrecht + Co has three offerings on file under the new Regulation A+, Hunting Dog Capital Corp., Aperion Biologics Inc. and Allegiancy Inc. “We at WR Hambrecht + Co continue to be astonished at the energy, inventiveness and sheer horsepower exhibited by early stage life sciences companies out to improve the human condition and build significant enterprises along the way,” said Kurt Kruger, Partner, and leader of the healthcare practice.
Kurt has enjoyed a 30 year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, Kruger developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed uncommon perspicuity leading Hambrecht & Quist to provide venture funds for, and then take public, Ventritex, a high profile, Wall Street darling that was later acquired by St. Jude Medical. Kruger received an Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan; and a business degree (S.M) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.